Kura Oncology (NASDAQ:KURA) Price Target Lowered to $14.00 at UBS Group

Kura Oncology (NASDAQ:KURA) had its price objective lowered by UBS Group from $27.00 to $14.00 in a research report report published on Thursday,Benzinga reports. UBS Group currently has a buy rating on the stock.

Other equities research analysts have also recently issued research reports about the stock. StockNews.com upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a research report on Thursday, February 27th. Cantor Fitzgerald upgraded shares of Kura Oncology to a “strong-buy” rating in a research report on Tuesday. JMP Securities restated a “market outperform” rating and issued a $28.00 price objective on shares of Kura Oncology in a research report on Thursday, February 6th. TD Cowen restated a “buy” rating on shares of Kura Oncology in a research report on Thursday, November 21st. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Kura Oncology in a research report on Thursday, February 27th. Three investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Kura Oncology has an average rating of “Moderate Buy” and a consensus target price of $25.50.

Kura Oncology Trading Up 4.5 %

Shares of Kura Oncology stock opened at $7.70 on Thursday. The stock has a market capitalization of $598.78 million, a P/E ratio of -3.26 and a beta of 0.85. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The company has a 50-day simple moving average of $8.04 and a 200 day simple moving average of $13.51. Kura Oncology has a 12-month low of $6.98 and a 12-month high of $24.17.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.43. The firm had revenue of $53.88 million for the quarter, compared to analyst estimates of $57.96 million. Research analysts expect that Kura Oncology will post -2.44 earnings per share for the current fiscal year.

Insider Transactions at Kura Oncology

In related news, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the transaction, the senior vice president now owns 88,193 shares of the company’s stock, valued at $694,078.91. This trade represents a 5.31 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the transaction, the insider now directly owns 88,253 shares in the company, valued at $694,551.11. The trade was a 5.32 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 11,729 shares of company stock worth $92,307 in the last quarter. 5.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Virtus ETF Advisers LLC boosted its stake in Kura Oncology by 71.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock worth $64,000 after acquiring an additional 3,061 shares during the last quarter. Point72 DIFC Ltd bought a new position in Kura Oncology during the 3rd quarter worth approximately $146,000. Harbor Advisors LLC bought a new position in Kura Oncology during the 4th quarter worth approximately $87,000. E Fund Management Co. Ltd. bought a new position in Kura Oncology during the 4th quarter worth approximately $90,000. Finally, Erste Asset Management GmbH bought a new position in Kura Oncology in the third quarter valued at approximately $215,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.